These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 27599663)

  • 21. Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations.
    Bastida C; Huitema ADR; l'Ami MJ; Ruiz-Esquide V; Wolbink GJ; Sanmartí R; Soy D
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1417-1425. PubMed ID: 32514745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.
    Tlustochowicz W; Rahman P; Seriolo B; Krammer G; Porter B; Widmer A; Richards HB
    J Rheumatol; 2016 Mar; 43(3):495-503. PubMed ID: 26834211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).
    Ohta S; Tsuru T; Terao K; Mogi S; Suzaki M; Shono E; Ishida Y; Tarumi E; Imai M
    J Clin Pharmacol; 2014 Jan; 54(1):109-19. PubMed ID: 24115082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
    Levi M; Grange S; Frey N
    J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
    Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.
    Khatri A; Goss S; Jiang P; Mansikka H; Othman AA
    Clin Pharmacokinet; 2018 May; 57(5):613-623. PubMed ID: 28744796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumab.
    Nakashima Y; Kondo M; Miyahara H; Iwamoto Y
    Drug Des Devel Ther; 2014; 8():913-9. PubMed ID: 25045250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Xu Y; Hu C; Zhuang Y; Hsu B; Xu Z; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):939-951. PubMed ID: 29578578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication.
    Hooijberg F; Layegh Z; Leeuw M; Boekel L; van den Berg SPH; Ruwaard J; Bastida C; Huitema ADR; Pel S; Elkayam O; de Vries A; Nurmohamed M; Rispens T; Dorlo TPC; Wolbink G
    Ther Drug Monit; 2024 Jun; 46(3):410-414. PubMed ID: 38287880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.
    Ternant D; Ducourau E; Fuzibet P; Vignault C; Watier H; Lequerré T; Le Loët X; Vittecoq O; Goupille P; Mulleman D; Paintaud G
    Br J Clin Pharmacol; 2015 Feb; 79(2):286-97. PubMed ID: 25223394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
    Smolen JS; Beaulieu A; Rubbert-Roth A; Ramos-Remus C; Rovensky J; Alecock E; Woodworth T; Alten R;
    Lancet; 2008 Mar; 371(9617):987-97. PubMed ID: 18358926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.
    Ogata A; Atsumi T; Fukuda T; Hirabayashi Y; Inaba M; Ishiguro N; Kai M; Kawabata D; Kida D; Kohsaka H; Matsumura R; Minota S; Mukai M; Sumida T; Takasugi K; Tamaki S; Takeuchi T; Ueda A; Yamamoto K; Yamanaka H; Yoshifuji H; Nomura A;
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1354-62. PubMed ID: 25832859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
    Yazici Y; Curtis JR; Ince A; Baraf H; Malamet RL; Teng LL; Kavanaugh A
    Ann Rheum Dis; 2012 Feb; 71(2):198-205. PubMed ID: 21949007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
    Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
    J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis.
    Li X; Roy A; Murthy B
    J Clin Pharmacol; 2019 Feb; 59(2):245-257. PubMed ID: 30229926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Ramanan AV; Horneff G; Cuttica R; Henrickson M; Anton J; Boteanu AL; Penades IC; Minden K; Schmeling H; Hufnagel M; Weiss JE; Pardeo M; Nanda K; Roth J; Rubio-Pérez N; Hsu JC; Wimalasundera S; Wells C; Bharucha K; Douglass W; Bao M; Mallalieu NL; Martini A; Lovell D; Benedetti F;
    Rheumatology (Oxford); 2021 Oct; 60(10):4568-4580. PubMed ID: 33506875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.